Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-914392 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment A: BMS-914392 | EXPERIMENTAL | - |
| Treatment B: BMS-914392 | EXPERIMENTAL | - |
| Treatment C: BMS-914392 | EXPERIMENTAL | - |
| Treatment D: Placebo | PLACEBO_COMPARATOR | - |
| metoprolol | OTHER | Treatment A |
| BMS-914392 + metoprolol | EXPERIMENTAL | Treatment B |
| Name | Type | Description |
|---|---|---|
| BMS-914392 | DRUG | Tablets, Oral, 10 mg, Every Day (QD), 20 days |
| Placebo | DRUG | Tablets, Oral, 0 mg, Three Times Daily (TID), 20 days |
| metoprolol | DRUG | Tablets, Oral, 200 mg, once, 1 day |
Inclusion Criteria: * Paroxysmal atrial fibrillation (AF) * Programmable dual chamber pacemaker with appropriate arrhythmia diagnostics. * 1-50% AF burden on pacemaker interrogation at screening. * Women of childbearing potential (WOCBP) and men must be using an acceptable method of contraception t...
BMS-914392 is an investigational small molecule being developed by Bristol-Myers Squibb for the treatment of atrial fibrillation, a condition characterized by an irregular and often rapid heart rate. It has been studied in clinical trials to evaluate its effects on atrial fibrillation burden and its potential interaction with other medications.
BMS-914392 is being developed by Bristol-Myers Squibb Company, a global biopharmaceutical company. The company's stock is traded under the ticker symbol BMY on the New York Stock Exchange. Bristol-Myers Squibb has conducted clinical trials to assess the safety and efficacy of BMS-914392 in patients with atrial fibrillation.
BMS-914392 is in Phase 2 clinical development. It has completed two clinical trials, including a Phase 1 study and a Phase 2 study, both of which have been completed. The drug is still investigational and has not been approved by regulatory authorities for the treatment of atrial fibrillation.
BMS-914392 has been studied in two completed clinical trials. The first, NCT01211821, was a Phase 1 study in the United States that evaluated the effect of BMS-914392 on the pharmacokinetics of metoprolol in healthy volunteers. The second, NCT01356914, was a Phase 2 study in the United Kingdom that assessed the effect of BMS-914392 on atrial fibrillation burden using pacemaker Holter monitoring.
BMS-914392 is not FDA approved. It is an investigational drug that has been evaluated in clinical trials for atrial fibrillation, but it has not received approval from the U.S. Food and Drug Administration or any other regulatory agency. The drug remains in clinical development and its safety and efficacy have not been fully established.